The 2025 Veeva MedTech Postmarket Quality Benchmark Report reveals a pivotal shift in the medical technology industry, with 88% of companies planning to advance postmarket quality systems within the next three years. This movement reflects growing recognition of the strategic role postmarket operations play—not only in ensuring regulatory compliance but also in driving innovation and responsiveness throughout the product lifecycle. As medtech companies face increasing complexity, patient safety expectations, and global regulatory demands, the modernization of quality systems has become an urgent priority.

The report underscores key challenges holding back progress, with 68% of companies still reliant on manual processes, paper-based methods, or outdated on-premise solutions. These inefficiencies result in delayed responses to product issues, backlogs in complaint handling, and increased exposure to compliance risks. However, the study also identifies strong momentum toward adopting scalable, cloud-based solutions that enable proactive risk management. Respondents cited the potential of advanced technologies such as automation, integrated analytics, and AI-driven reporting to accelerate decision-making, enhance efficiency, and support long-term growth.

Despite limited adoption of emerging technologies like generative AI and robotic process automation—currently used by fewer than 3% of respondents—there is clear optimism about their potential. The report also highlights a critical gap in workforce readiness, with only 19% of companies confident in their current employee training programs. These findings collectively signal a broader industry transformation: medtech leaders increasingly view postmarket quality not as a compliance burden, but as a strategic advantage. By embracing modern systems, building agile teams, and acting on real-time data, companies are poised to improve patient outcomes, safeguard brand trust, and lead the next wave of innovation in healthcare.

MedTech Spectrum's Summary

Industry-Wide Modernization: 88% of medtech companies plan to advance their postmarket quality systems by 2028, signaling a strategic shift toward proactive, risk-based quality management.

Technology as a Catalyst: While 68% still rely on manual or legacy systems, there is strong momentum to adopt scalable digital tools, with automation and AI seen as key enablers of faster, more efficient quality operations.

Opportunity for Competitive Advantage: Modernizing postmarket quality is no longer just about compliance—it's a critical driver of innovation, operational agility, and long-term success in an increasingly complex healthcare landscape.